Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug

Respirology

Volumn 11, Issue 5, 2006, Pages 663-665

  Wardwell Jr , Noel R ^a   Miller, Robert ^a   Ware, Lorraine B ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antirheumatic agent; Granulocyte macrophage colony stimulating factor; Leflunomide; Pulmonary alveolar proteinosis; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; HUMAN; LUNG ALVEOLUS PROTEINOSIS; LUNG BIOPSY; LUNG LAVAGE; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; ISOXAZOLES; MALE; PULMONARY ALVEOLAR PROTEINOSIS;

EID: 33746911926     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00905.x     Document Type: Article

References (14)

1. Ben-Dov I, Kishinevski Y, Roznman J et al. Pulmonary alveolar proteinosis in Israel: ethnic clustering. Isr. Med. Assoc. J. 1999; 1: 75-8.
2. Kitamura T, Tanaka N, Watanabe J et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1999; 190: 875-80.
3. Kitamura T, Uchida K, Tanaka N et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 2000; 162: 658-62.
4. Tanaka N, Watanabe J, Kitamura T et al. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocytemacrophage colony stimulating factor. FEBS Lett. 1999; 442: 246-50.
5. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am. J. Respir. Crit. Care Med. 2002; 166: 215-35.
6. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N. Engl. J. Med. 2003; 349: 2527-39.
7. Ladeb S, Fleury-Feith J, Escudier E et al. Secondary alveolar proteinosis in cancer patients. Support. Care Cancer 1996; 4: 420-6.
8. Cordonnier C, Fleury-Feith J, Escudier E et al. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am. J. Respir. Crit. Care Med. 1994; 149: 788-94.
9. Yousem SA. Alveolar lipoproteinosis in lung allograft recipients. Hum. Pathol. 1997; 28: 1383-6.
10. Samuels MP, Warner JO. Pulmonary alveolar lipoproteinosis complicating juvenile dermatomyositis. Thorax 1988; 43: 939-40.
11. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 2000; 165: 5962-9.
12. Siemasko K, Chong AS, Jack HM et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 1998; 160: 1581-8.
13. Xu X, Shen J, Mall JW et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem. Pharmacol. 1999; 58: 1405-13.
14. Cutolo M, Sulli A, Ghiorzo P et al. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann. Rheum. Dis. 2003; 62: 297-302.